1. Synthesis, biological evaluation, and molecular docking studies of aldotetronic acid-based LpxC inhibitors
- Author
-
Stefan, Wimmer, Katharina, Hoff, Benedikt, Martin, Martin, Grewer, Laura, Denni, Raquel, Lascorz Massanet, Maria Valeria, Raimondi, Emre F, Bülbül, Jelena, Melesina, Sven-Kevin, Hotop, Jörg, Haupenthal, Holger, Rohde, Peter, Heisig, Anna K H, Hirsch, Mark, Brönstrup, Wolfgang, Sippl, Ralph, Holl, Wimmer, Stefan, Hoff, Katharina, Martin, Benedikt, Grewer, Martin, Denni, Laura, Lascorz Massanet, Raquel, Raimondi, Maria Valeria, Bülbül, Emre F, Melesina, Jelena, Hotop, Sven-Kevin, Haupenthal, Jörg, Rohde, Holger, Heisig, Peter, Hirsch, Anna K H, Brönstrup, Mark, Sippl, Wolfgang, and Holl, Ralph
- Subjects
Antibiotics ,Bacterial uptake ,LpxC inhibitors ,Organic Chemistry ,Drug Discovery ,Aldotetronic acid derivatives ,Molecular-docking studies ,LasB ,Molecular Biology ,Biochemistry ,Settore CHIM/08 - Chimica Farmaceutica - Abstract
In order to develop novel inhibitors of the bacterial deacetylase LpxC bearing a substituent to target the UDP binding site of the enzyme, a series of aldotetronic acid-based hydroxamic acids was accessed in chiral pool syntheses starting from 4,6-O-benzylidene-d-glucose and l-arabinitol. The synthesized hydroxamic acids were tested for LpxC inhibitory activity in vitro, revealing benzyl ether 17a ((2S,3S)-4-(benzyloxy)-N,3-dihydroxy-2-[(4-{[4-(morpholinomethyl)phenyl]ethynyl}benzyl)oxy]butanamide) as the most potent LpxC inhibitor. This compound was additionally tested for antibacterial activity against a panel of clinically relevant Gram-negative bacteria, bacterial uptake, and susceptibility to efflux pumps. Molecular docking studies were performed to rationalize the observed structure-activity relationships.
- Published
- 2022